Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasiglifam vs Glimepiride in T2DM on Metformin
NCT01481116Phase 3Terminated
- Sponsor
- Takeda
- Start
- Jan 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of fasiglifam in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Takeda. Primary endpoint: Change From Baseline in HbA1c at 104 weeks. Started Jan 2012; status: terminated.
02
Drugs
fasiglifam
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01481116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01481116.